Terms: = Ovarian cancer AND CBFA2T3, ETO2, 863, ENSG00000129993, ZMYND4, MTGR2, MTG16
40 results:
1. Diagnosis Shift in Site of Origin of Tubo-ovarian Carcinoma.
Lee MW; Anderson ZS; Girma AM; Klar M; Roman LD; Carlson JW; Wright JD; Sood AK; Matsuo K
Obstet Gynecol; 2024 May; 143(5):660-669. PubMed ID: 38513238
[TBL] [Abstract] [Full Text] [Related]
2. A blood-based metabolomic signature predictive of risk for pancreatic cancer.
Irajizad E; Kenney A; Tang T; Vykoukal J; Wu R; Murage E; Dennison JB; Sans M; Long JP; Loftus M; Chabot JA; Kluger MD; Kastrinos F; Brais L; Babic A; Jajoo K; Lee LS; Clancy TE; Ng K; Bullock A; Genkinger JM; Maitra A; Do KA; Yu B; Wolpin BM; Hanash S; Fahrmann JF
Cell Rep Med; 2023 Sep; 4(9):101194. PubMed ID: 37729870
[TBL] [Abstract] [Full Text] [Related]
3. Seeing beyond the tumor: computed tomography image-based radiomic analysis helps identify ovarian clear cell carcinoma subtype in epithelial ovarian cancer.
Ren J; Mao L; Zhao J; Li XL; Wang C; Liu XY; Jin ZY; He YL; Li Y; Xue HD
Radiol Med; 2023 Aug; 128(8):900-911. PubMed ID: 37368228
[TBL] [Abstract] [Full Text] [Related]
4. Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Kase AM; Azzouqa AG; Kochuveettil S; Colon-Otero G
Cancer Med; 2023 Apr; 12(8):9434-9438. PubMed ID: 36806695
[TBL] [Abstract] [Full Text] [Related]
5. Diffusion-Weighted Magnetic Resonance Imaging and Morphological Characteristics Evaluation for Outcome Prediction of Primary Debulking Surgery for Advanced High-Grade Serous ovarian Carcinoma.
Li H; Lu J; Deng L; Guo Q; Lin Z; Zhao S; Ge H; Qiang J; Gu Y; Liu Z
J Magn Reson Imaging; 2023 May; 57(5):1340-1349. PubMed ID: 36054024
[TBL] [Abstract] [Full Text] [Related]
6. Associations of genetic risk, BMI trajectories, and the risk of non-small cell lung cancer: a population-based cohort study.
You D; Wang D; Wu Y; Chen X; Shao F; Wei Y; Zhang R; Lange T; Ma H; Xu H; Hu Z; Christiani DC; Shen H; Chen F; Zhao Y
BMC Med; 2022 Jun; 20(1):203. PubMed ID: 35658861
[TBL] [Abstract] [Full Text] [Related]
7. Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses.
Tanha K; Mottaghi A; Nojomi M; Moradi M; Rajabzadeh R; Lotfi S; Janani L
J Ovarian Res; 2021 Nov; 14(1):153. PubMed ID: 34758846
[TBL] [Abstract] [Full Text] [Related]
8. Predictors of malignancy in incidental adnexal lesions identified on CT in patients with prior non-ovarian cancer.
Shinagare AB; Gujrathi I; Cochon L; Burk KS; Sadowski E; Khorasani R
Abdom Radiol (NY); 2022 Jan; 47(1):320-327. PubMed ID: 34468797
[TBL] [Abstract] [Full Text] [Related]
9. Long Noncoding RNA LINC01554 as a Novel Biomarker for Diagnosis and Prognosis Prediction of Epithelial ovarian cancer.
Luo T; Jiang Y; Yang J
Dis Markers; 2021; 2021():1244612. PubMed ID: 34422133
[TBL] [Abstract] [Full Text] [Related]
10. Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study.
Yuk JS; Lee B; Kim K; Kim MH; Seo YS; Hwang SO; Yoon SH; Kim YB
PLoS One; 2021; 16(4):e0250723. PubMed ID: 33909674
[TBL] [Abstract] [Full Text] [Related]
11. [Bioinformatics analysis of drug-resistant ceRNA in epithelial ovarian cancer].
Pan ZM; Tan FC; Chen CX; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2021 Feb; 56(2):121-130. PubMed ID: 33631884
[No Abstract] [Full Text] [Related]
12. Chronic inflammation towards cancer incidence: A systematic review and meta-analysis of epidemiological studies.
Michels N; van Aart C; Morisse J; Mullee A; Huybrechts I
Crit Rev Oncol Hematol; 2021 Jan; 157():103177. PubMed ID: 33264718
[TBL] [Abstract] [Full Text] [Related]
13. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
Vergote I; du Bois A; Floquet A; Rau J; Kim JW; Del Campo JM; Friedlander M; Pignata S; Fujiwara K; Colombo N; Mirza MR; Monk BJ; Tsibulak I; Calvert PM; Herzog TJ; Hanker LC; Meunier J; Lee JY; Bologna A; Carrasco-Alfonso MJ; Harter P
Gynecol Oncol; 2019 Nov; 155(2):186-191. PubMed ID: 31519320
[TBL] [Abstract] [Full Text] [Related]
14. Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous ovarian Carcinomas.
Sari A; Pollett A; Eiriksson LR; Lumsden-Johanson B; Van de Laar E; Kazerouni H; Salehi A; Sur M; Lytwyn A; Ferguson SE
Am J Surg Pathol; 2019 May; 43(5):591-600. PubMed ID: 30864976
[TBL] [Abstract] [Full Text] [Related]
15. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors.
Horała A; Swiatly A; Lorek J; Kokot ZJ; Matysiak J; Nowak-Markwitz E
Ginekol Pol; 2018; 89(10):568-572. PubMed ID: 30393846
[TBL] [Abstract] [Full Text] [Related]
16. Postoperative chemotherapy had no prognostic effect on early-staged young ovarian cancer with unilateral resection.
Zhang X; Wang S; Zhao S; Sun Y; Yang G
Cancer Med; 2018 Nov; 7(11):5488-5496. PubMed ID: 30306725
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy.
Teh BH; Yong SL; Sim WW; Lau KB; Suharjono HN
Horm Mol Biol Clin Investig; 2018 Jul; 35(1):. PubMed ID: 30063463
[TBL] [Abstract] [Full Text] [Related]
18. Preoperative prediction of deep myometrial invasion and tumor grade for stage I endometrioid adenocarcinoma: a simple method of measurement on DWI.
Yan B; Liang X; Zhao T; Niu C; Ding C; Liu W
Eur Radiol; 2019 Feb; 29(2):838-848. PubMed ID: 30039225
[TBL] [Abstract] [Full Text] [Related]
19. Predictive Factors for Surgical Morbidities and Adjuvant Chemotherapy Delay for Advanced ovarian cancer Patients Treated by Primary Debulking Surgery or Interval Debulking Surgery.
Castro BGR; Dos Reis R; Cintra GF; Sousa MMA; Vieira MA; Andrade CEMDC
Int J Gynecol Cancer; 2018 Oct; 28(8):1520-1528. PubMed ID: 30036229
[TBL] [Abstract] [Full Text] [Related]
20. Survival Disparities by Hospital Volume Among American Women With Gynecologic cancers.
Seagle BL; Strohl AE; Dandapani M; Nieves-Neira W; Shahabi S
JCO Clin Cancer Inform; 2017 Nov; 1():1-15. PubMed ID: 30657373
[TBL] [Abstract] [Full Text] [Related]
[Next]
